<DOC>
	<DOCNO>NCT02041195</DOCNO>
	<brief_summary>The purpose study evaluate effect new daily subcutaneous ( SC ) injectable formulation RM-493 healthy obese subject mean percent body weight loss weight loss parameter , well Pharmacokinetic ( PK ) profile . The study design evaluate efficacy tolerability RM-493 administer twice daily . The study drug ( RM-493 placebo ) administer blinded fashion .</brief_summary>
	<brief_title>Phase 1b/2a Study Evaluate Safety Efficacy RM-493 Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<criteria>Be age 18 65 inclusive . Able provide voluntary , write informed consent comprehension aspect protocol , prior study procedure . In good general health , without significant medical history , physical examination finding , clinical laboratory abnormality . Body Mass Index : 30 40 Kg/m2 . Stable body weight subject report ( +/ 5 Kg ) previous 6 month . Blood pressure ( &lt; 140/90 mmHg ) ; may include stable dose ( ≥ 30 day use ) two antihypertensive medication achieve control intend remain stable dose protocol . Patients slightly range participate discretion investigator . Willingness ( screen ) demonstrate ability ( witness clinic prior randomization ) selfadminister study medication subcutaneously via twice daily SC injection use small insulin syringe . Willing maintain healthy diet exercise regime throughout study recommend counsel study start . Female subject must negative serum pregnancy test must lactate . For female able bear child , hormonal ( i.e. , oral , implantable , injectable ) singlebarrier method ( i.e. , sponge ) , doublebarrier method birth control ( i.e. , condom spermicide ) abstinence must used/ practice throughout study 90 day follow study . Females nonchildbearing potential , define surgically sterile ( status post hysterectomy , bilateral oophorectomy , bilateral tubal ligation ) postmenopausal least 12 month ( confirm screen FSH level postmenopausal lab range ) , require contraception study . Males female partner childbearing potential must agree double barrier method become sexually active study 90 day follow study . Male subject must donate sperm 90 day follow participation study . Fasting blood glucose &gt; 140 mg/dL . TSH level outside normal range . Creatinine &gt; 1.5 time upper limit normal . Liver function test &gt; 2 time upper limit normal . Active history significant medical condition include renal , hepatic , pulmonary , gastrointestinal , cardiovascular , genitourinary , endocrine , immunologic , metabolic , neurologic hematological disease . Patients history follow : 1 . Uncontrolled hypertension ; 2 . Diabetes require medical treatment ; 3 . Major depressive disorder within last 2 year ; 4 . Any lifetime history suicide attempt ; 5 . Any suicidal ideation/behavior last month ; 6 . Other severe psychiatric disorder ( e.g . schizophrenia , bipolar disorder , severe eat disorder include bulimia ) . A PHQ9 score ≥15 . Any suicidal ideation type 4 5 CSSRS . Prior bariatric surgery . History close family history ( parent sibling ) melanoma . Significant dermatologic finding part Screening comprehensive skin evaluation perform dermatologist . Any concern lesion identify screening period biopsied result know benign prior randomization . If pretreatment biopsy result concern , patient exclude study . Currently treat anorectic agent drug last 2 month screen anorexia frequent side event . Taking 2 antihypertensive medication . Acute illness history illness , opinion Investigator , could pose threat harm patient obscure interpretation laboratory test result interpretation study data . History malignancy , past present , include skin cancer , multiple severely dysplastic nevus , nevoid basal cell carcinoma . History HIV infection Hepatitis B C. History significant drug hypersensitivity anaphylaxis . History hypersensitivity protein ( e.g. , allergy shot ) . Any clinically significant abnormality screen laboratory determine Investigator . Abnormal 12lead electrocardiogram ( ECG ) screening , except minor deviation deem clinical significance Investigator . QTcF must &lt; 450 m . Received experimental drug device participate clinical study within 30 day prior dose . Blood donation great 500 mL within 60 day prior screen intent donate 30 day Final Study Visit . Hospitalization surgery within 3 month prior screen except minor outpatient procedure , plan hospitalization study period . Poor venous access inability tolerate venipuncture . Inability attend study visit comply protocol requirement include fast restriction concomitant medication intake . Participation weight loss program study period , include nutritional supplements/ replacement recommend nutritional counseling provide study start . Use prescription medication regular basis follow exception : 1 . Contraceptives ( must ≥3 month ) ; 2 . Hormone replacement therapy ( must stable dose ≥3 month ) ; 3 . Antihypertensives ( &lt; 2 medication stable dose ≥ 30 day ) ; 4 . Statins ( dose must ≤ half maximum dose ; must stable dose ≥3 month ) ; 5 . Thyroxin ( stable dose ≥ 30 day ) ; 6 . The last use prescription medication must great 5 halflives specific medication least 14 day prior randomization , whichever longer . Women pregnant breast feeding . Previously randomize dose study previously expose RM493 . History alcohol drug abuse within 5 year Screening Visit . Any reason , opinion Investigator would confound proper evaluation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Overweight</keyword>
</DOC>